PK/PD Relationship of CAZ/AVI and FOS in the Treatment of Patients With Infections Due to CRE

Recruiting now

Conditions studied: Gram Negative Infections, Antimicrobial Resistance (AMR)

In brief

A multicenter international prospective observational pharmacological study in adult patients (≥18 years) treated with ceftazidime/avibactam (CAZ/AVI) alone or with CAZ/AVI plus fosfomycin (FOS) for infection due to carbapenem-resistant Enterobacterales (CRE) (KPC and/or OXA-48).

Key facts

Study ID

NCT06717594

Run by

IRCCS Azienda Ospedaliero-Universitaria di Bologna

People needed

60

Starts

2023-12-01

Expected to finish

2026-12-31

Last updated by the study team

2026-06-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signature of the informed consent
• Age ≥ 18 years
• Adult patients treated for ≥ 48 hours with CAZ/AVI or CAZ/AVI plus FOS for a microbiologically documented CRE infection

You may not qualify if…

• Polymicrobial/mixed infections with exception of cases with multiple Enterobacterales susceptible to study drugs

Where it is running

• IRCCS Azienda Ospedaliero-Universitaria di Bologna — Bologna, Bologna, Italy (enrolling)
• Instituto de Biomedicina de Sevilla (IBiS), Hospital Virgen Macarena/CSIC/Universidad de Sevilla — Seville, Seville, Spain (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.